Abstract | RATIONALE: PATIENT CONCERNS: In August 2014, a 28-year-old premenopausal woman noted a mass that was approximately 3.0 cm*2.0 cm in size on her right breast with pain. Subsequently, the mass has been always increasing significantly. In August 2015, the mass was approximately 7.0 cm*5.0 cm in size, accompanied by pain, no nipple retraction and discharge, no orange peel-like skin changes, and no dimples. In addition, she had no salient past history. DIAGNOSES: Histopathological examinations by a biopsy with a thick needle (hollow needle) and surgical resection confirmed poorly differentiated neuroendocrine carcinoma of the right breast. INTERVENTIONS: OUTCOMES: According to response evaluation criteria in solid tumors 1.1, the tumor was shrunk by 78.87% after neoadjuvant endocrine therapy. No salient complications were observed. We have followed her for 48 months, and there are no signs of recurrence and metastasis. LESSONS:
|
Authors | Yonglin Zhang, Chao Liu, Chaoting Zheng, Qiaozhen Ren, Qimin Wang, Xinyi Gao, Yushuang He, Jierong Wu, Guanglei Chen, Xuelu Li, Zhenhai Ma |
Journal | Medicine
(Medicine (Baltimore))
Vol. 99
Issue 43
Pg. e22652
(Oct 23 2020)
ISSN: 1536-5964 [Electronic] United States |
PMID | 33120755
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Hormonal
- Aromatase Inhibitors
- Goserelin
- Letrozole
|
Topics |
- Adult
- Antineoplastic Agents, Hormonal
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Aromatase Inhibitors
(administration & dosage)
- Breast Neoplasms
(diagnosis, drug therapy, pathology)
- Carcinoma, Neuroendocrine
(diagnosis, drug therapy, pathology)
- Female
- Goserelin
(administration & dosage)
- Humans
- Letrozole
(administration & dosage)
- Neoadjuvant Therapy
(methods)
|